AsianScientist (Sep. 13, 2016) – WuXi AppTec, a medical device and biologics testing company headquartered in Shanghai, has announced that its laboratory testing division has entered into an exclusive distributor agreement with US-based AutoGenomics, a company that makes diagnostic microarray platforms.
Under the agreement, WuXi will manufacture, register and distribute AutoGenomics’ INFINITI® molecular diagnostic systems and related reagent and consumable products in China. WuXi will license the assembly and manufacturing of the INFINITI® Systems in China.
The two companies will also collaborate to develop and commercialize new clinical diagnostic tests that are specifically designed for China’s healthcare market.
“WuXi is committed to China’s healthcare advancement and national precision medicine plan through active collaboration with doctors, scientists, companies and policy makers,” said Dr. Ge Li, chairman and CEO of WuXi.
“We will continue to help advance precision medicine and personalized treatment by introducing more cutting edge technologies, accelerating science from research bench to hospital beds, and ultimately benefiting the general public.”
———
Source: Wuxi AppTec; Photo: WuXi Apptec & AutoGenomics.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
